DUBLIN, July 9, 2019 /PRNewswire/ -- Allergan plc (NYSE:
AGN) announced today that the company will present 29 abstracts at
the 61st American Headache Society (AHS) Meeting,
including one late-breaking podium presentation, five oral podium
presentations and 23 poster presentations. The presentations will
continue to highlight Allergan's ongoing innovation in the
treatment and understanding of migraine disease, bringing forth new
data and insights across its expanding migraine franchise.
With an expected FDA decision in Q4 2019, Allergan continues to
highlight data from its pivotal trials for ubrogepant, an
investigational oral CGRP receptor antagonist for the acute
treatment of migraine. Allergan will present a total of 14
ubrogepant focused abstracts, including ubrogepant in patients
ineffectively treated with triptans, the effectiveness and safety
of a second optional dose in achieving pain freedom at 2 hours, the
safety of ubrogepant in patients with moderate to high
cardiovascular risk, and the onset of pain relief.
BOTOX® (onabotulinumtoxinA) remains a mainstay in the
preventive treatment space and is a first-line treatment for
Chronic Migraine. BOTOX® will be featured in several
presentations focused on safety, efficacy, and healthcare resource
utilization with data evaluating impact on headache severity,
headache-related impact, and quality of life in responder and
nonresponder subgroups, and reductions in healthcare resource
utilization. In addition, preclinical data from a mechanism of
action study will be presented. This study evaluated a potential
Chronic Migraine treatment approach that combines BOTOX®
and atogepant, the company's second investigational,
orally-administered CGRP receptor antagonist. Atogepant is
currently in Phase III clinical trials for the prevention of
migraine and will be highlighted in four abstracts at this year's
meeting.
"The strength of our data at AHS reinforces Allergan's heritage
and innovation in the migraine treatment space," said
David Nicholson, Chief Research and
Development Officer, Allergan. "With a wealth of presentations
highlighting BOTOX®, ubrogepant and atogepant,
Allergan is proud to showcase our ongoing commitment to the
scientific advancement of our migraine franchise – Allergan
MIND™ – and to the migraine community at large." As part
of Allergan's ongoing commitment to innovating and
inspiring change in the migraine community, the company has
established a migraine franchise, Allergan MIND™ (Migraine:
Innovation, Navigation, Discovery), to drive progress and unify its
efforts as a worldwide leader in migraine.
The following late-breaking platform presentation will be
highlighted on Saturday, July
13th at 11:30 AM
ET:
- Extracranial injections of onabotulinumtoxinA in combination
with intravenous injection of atogepant attenuates activation and
sensitization of HT and WDR neurons by CSD. Authors: Agustin M,
et al.
Oral podium presentations include:
- Demographics, Headache Characteristics, and Other Factors
Associated With Opioid Use in People With Migraine: Results From
the CaMEO Study. Authors: Lipton R, et al. Friday, July 12th, 12:10
PM ET.
- Orally Administered Atogepant Was Efficacious, Safe, and
Tolerable for the Prevention of Migraine: Results From a Phase
2b/3 Study. Authors: Goadsby
P, et al. Saturday, July 13th,
8:00 AM ET.
- Ubrogepant is Effective for the Acute Treatment of Migraine
in Patients for Whom Triptans are Ineffective. Authors:
Blumenfeld AM, et al. Saturday, July
13th, 8:10 AM ET. (ePoster to
be highlighted on Saturday, July
13th from 1:30 PM –
1:35 PM ET)
- Results from the Chronic Migraine Epidemiology and Outcomes
(CaMEO) Study Demonstrate a High Level of Unmet Need for Migraine
Treatment in People Who Discontinue Acute Prescription Migraine
Medication. Authors: Lipton R, et al. Saturday, July 13th, 9:20
AM ET.
- Characterization of the Effects of the Calcitonin
Gene–Related Peptide (CGRP) Receptor Antagonists Atogepant and
Ubrogepant on Isolated Human Coronary, Cerebral, and Middle
Meningeal Arteries. Authors: Rubio-Beltran E, et al.
Saturday, July 13th, 11:10 AM ET.
The following posters will be displayed on Friday, July 12th from 1:15 PM – 2:15 PM
ET:
- The Impact of OnabotulinumtoxinA vs Placebo on Efficacy
Outcomes in Responder and Nonresponder Subgroups of Patients with
Chronic Migraine: PREEMPT Pooled Analysis. Authors: Diener
HC, et al. (ePoster to be highlighted on Saturday, July 13th from 1:15 PM – 2:15 PM
ET)
- Safety and Tolerability of Ubrogepant Following
Intermittent, High Frequency Dosing. Authors: Goadsby P,
et al.
- Triptan Discontinuation and Treatment Patterns Among
Migraine Patients Initiating Triptan Treatment in a US Commercially
Insured Population. Authors: Marcus S, et al.
- Greater Headache-Related Burden and Disability Among Those
with Medication Overuse: Results from the Chronic Migraine
Epidemiology and Outcomes (CaMEO) Study. Authors: Schwedt
TJ, et al. (ePoster to be highlighted on Saturday, July 13th from 1:50 PM – 1:55 PM
ET)
- Health-Related Quality of Life Based on Response to Triptans
in People With Migraine: Analysis of Real-World
Data. Authors: Lipton RB, et al.
- Single Therapeutic Doses of Ubrogepant Are Not Associated
with a Clinically Relevant Drug-Drug Interaction When
Co-administered with Acetaminophen or Naproxen. Authors: Jakate
A, et al. (ePoster to be highlighted on Saturday, July 13th from 1:40 PM – 1:45 PM
ET)
- Absence of Clinically Significant Drug Interactions With
Coadministration of Ubrogepant and an Ethinyl
Estradiol/Norgestimate Oral Contraceptive in Healthy Female
Subjects: A Phase 1 Pharmacokinetic Analysis. Authors: Li
CC, et al. (ePoster to be highlighted on Friday, July 12th or Saturday, July 13th from 1:15 PM – 2:15 PM
ET)
- An Optional Second Dose of Ubrogepant is Effective in
Achieving 2-Hour Pain Freedom in the Acute Treatment of
Migraine. Authors: Ailani J, et al. (ePoster to be
highlighted on Saturday, July
13th from 1:10 PM –
1:15 PM ET)
- Safety and Efficacy of Ubrogepant in Participants with
Moderate to High Cardiovascular Risk. Authors: Hutchinson
S, et al. (ePoster to be highlighted on Friday, July 12th or Saturday, July 13th from 1:15 PM – 2:15 PM
ET)
- Healthcare Resource Utilization in Adult Patients Treated
with OnabotulinumtoxinA for Chronic Migraine: Results from the
COMPEL Study. Authors: Rothrock JF, et al. (ePoster
to be highlighted on Saturday, July
13th from 1:15 PM –
1:20 PM ET)
- Ubrogepant for the Acute Treatment of Migraine: Pooled
Safety and Tolerability from ACHIEVE I and ACHIEVE II Phase 3
Studies. Authors: Hutchinson S, et al. (ePoster to be
highlighted on Saturday, July
13th from 1:30 PM –
1:35 PM ET)
- Depression and Anxiety Are Associated With Increased
Headache-Related Disability in Episodic and Chronic Migraine:
Results From the Chronic Migraine Epidemiology and Outcomes (CaMEO)
Study. Authors: Lipton RB, et al. (ePoster to be
highlighted on Saturday, July
13th from 1:05 PM –
1:10 PM ET)
- Single Therapeutic and Supratherapeutic Doses of Ubrogepant
Do Not Affect Cardiac Repolarization in Healthy Adults.
Authors: Jakate A, et al. (ePoster to be highlighted on
Friday, July 12th from
1:40 PM – 1:45
PM ET)
The following posters will be displayed on Saturday, July 13th from 1:00 PM – 2:15 PM
ET:
- Characterization of Ubrogepant: A Potent and Selective
Antagonist of the Human Calcitonin Gene‒Related Peptide Receptor.
Authors: Moore E, et al.
- Responder Rates to Atogepant in Patients With Episodic
Migraine: A Post Hoc Analysis of Results From a Phase 2b/3, Randomized, Double-Blind,
Placebo-Controlled Trial. Authors: Dodick DW, et al.
- Opioid Use, Rebound Headache, and Resource Utilization Among
Migraine Patients With Insufficient Response to Triptans Based on
Real-World Data. Authors: Silberstein SD, et
al. (ePoster to be highlighted on Friday, July 12th from 1:25 PM – 1:30 PM
ET)
- Analysis of Treatment Change of Acute Prescription Migraine
Medications Using Real-World Evidence. Authors: Lipton RB,
et al. (ePoster to be highlighted on Friday, July 12th from 1:30 PM – 1:35 PM
ET)
- Coadministration of Single Therapeutic Oral Doses of
Ubrogepant and Sumatriptan Produces No Clinically Relevant
Pharmacokinetic Interactions. Authors: Jakate A, et
al. (ePoster to be highlighted on Friday, July 12th from 1:45 PM – 1:50 PM
ET)
- Absence of Clinically Significant Drug Interactions With
Coadministration of Atogepant and an Ethinyl
Estradiol/Levonorgestrel Oral Contraceptive in Healthy Female
Subjects: A Phase 1 Pharmacokinetic Analysis. Authors:
Ankrom W, et al. (ePoster to be highlighted on Friday, July 12th or Saturday, July 13th from 1:15 PM – 2:15 PM
ET)
- Ubrogepant Achieves Early Pain Relief for the Acute
Treatment of Migraine. Authors: Dodick DW, et al.
- Long-term Safety Evaluation of Ubrogepant for the Acute
Treatment of Migraine Attacks. Authors: Ailani J, et
al. (ePoster to be highlighted on Friday, July 12th from 1:25 PM – 1:30 PM
ET)
- Efficacy is Maintained with Long-term Intermittent Use of
Ubrogepant for the Acute Treatment of Migraine. Authors:
Lipton RB, et al. (ePoster to be highlighted on Friday, July 12th from 1:40 PM – 1:45 PM
ET)
- OnabotulinumtoxinA Is Safe and Effective in Patients Who
Discontinue Topiramate: Results of the FORWARD
Study. Authors: Rothrock JF, et al. (ePoster to be
highlighted on Friday, July
12th from 1:40 PM –
1:45 PM ET)
Indication
BOTOX® is a prescription medicine that is injected
into muscles and used:
- To prevent headaches in adults with Chronic Migraine who have
15 or more days each month with headache lasting 4 or more hours
each day in people 18 years or older
It is not known whether BOTOX® is safe or effective
to prevent headaches in patients with migraine who have 14 or fewer
headache days each month (episodic migraine).
IMPORTANT SAFETY INFORMATION
BOTOX® may cause serious side effects
that can be life threatening. Get medical help right away if you
have any of these problems any time (hours to weeks) after
injection of BOTOX®:
- Problems swallowing, speaking, or breathing, due to
weakening of associated muscles, can be severe and result in loss
of life. You are at highest risk if these problems are pre-existing
before injection. Swallowing problems may last for several
months.
- Spread of toxin effects. The effect of botulinum toxin
may affect areas away from the injection site and cause serious
symptoms including: loss of strength and all-over muscle weakness,
double vision, blurred vision and drooping eyelids, hoarseness or
change or loss of voice, trouble saying words clearly, loss of
bladder control, trouble breathing, trouble swallowing.
There has not been a confirmed serious case of spread of toxin
effect away from the injection site when BOTOX® has
been used at the recommended dose to treat chronic
migraine.
BOTOX® may cause loss of strength or general
muscle weakness, vision problems, or dizziness within hours to
weeks of taking BOTOX®. If this happens, do not drive
a car, operate machinery, or do other dangerous activities.
Do not receive BOTOX® if you: are
allergic to any of its ingredients (see Medication Guide for
ingredients); had an allergic reaction to any other botulinum toxin
product such as
Myobloc® (rimabotulinumtoxinB),
Dysport® (abobotulinumtoxinA), or
Xeomin® (incobotulinumtoxinA); have a skin
infection at the planned injection site.
The dose of BOTOX® is not the same as,
or comparable to, another botulinum toxin product.
Serious and/or immediate allergic reactions have been
reported, including itching, rash, red itchy welts, wheezing,
asthma symptoms, or dizziness or feeling faint. Get medical help
right away if you experience symptoms; further injection of
BOTOX® should be discontinued.
Tell your doctor about all your muscle or nerve
conditions such as ALS or Lou
Gehrig's disease, myasthenia gravis, or Lambert-Eaton
syndrome, as you may be at increased risk of serious side effects
including difficulty swallowing and difficulty breathing from
typical doses of BOTOX®.
Tell your doctor about all your medical conditions, including
if you: have or have had bleeding problems; have plans to have
surgery; had surgery on your face; weakness of forehead muscles;
trouble raising your eyebrows; drooping eyelids; any other abnormal
facial change; are pregnant or plan to become pregnant (it is not
known if BOTOX® can harm your unborn baby); are
breastfeeding or plan to (it is not known if BOTOX®
passes into breast milk).
Tell your doctor about all the medicines you take,
including prescription and over-the-counter medicines, vitamins,
and herbal supplements. Using BOTOX® with certain
medicines may cause serious side effects. Do not start any new
medicines until you have told your doctor that you received
BOTOX® in the past.
Tell your doctor if you received any other botulinum toxin
product in the last 4 months; have received injections of botulinum
toxin such as Myobloc®,
Dysport®, or Xeomin® in the
past (tell your doctor exactly which product you received); have
recently received an antibiotic injection; take muscle relaxants;
take allergy or cold medicines; take sleep medicine; take
aspirin-like products or blood thinners.
Other side effects of
BOTOX® include: dry mouth, discomfort or
pain at injection site, tiredness, headache, neck pain, eye
problems: double vision, blurred vision, decreased eyesight,
drooping eyelids, swelling of eyelids, and dry eyes; drooping
eyebrows.
For more information refer to the Medication Guide or talk with
your doctor. You are encouraged to report negative side effects of
prescription drugs to the FDA. Visit www.fda.gov/medwatch or
call 1-800-FDA-1088.
Please see BOTOX® full Product
Information including Boxed Warning and Medication
Guide.
About Ubrogepant
Ubrogepant is an orally-administered CGRP receptor antagonist in
development for the acute treatment of migraine. CGRP and its
receptors are expressed in regions of the nervous system associated
with migraine pathophysiology. CGRP receptor antagonism is a novel
mechanism of action for the acute treatment of migraine that
differs from the mechanisms of currently available triptans
(serotonin 1B/1D agonists), opioids
and ergots.
About Atogepant
Atogepant is an orally-administered CGRP receptor antagonist in
development for the prevention of migraine. CGRP and its receptors
are expressed in regions of the nervous system associated with
migraine pathophysiology. It is chemically distinct from
ubrogepant, our investigational orally-administered CGRP receptor
antagonist for the acute treatment of migraine, and has
demonstrated in preclinical studies to have a higher potency and
longer half-life, making it potentially suitable for preventive
treatment.
About Migraine Disease
Migraine is a chronic disease with episodic attacks defined by
neurological symptoms such as headache pain, sensitivity to light
and sound, and nausea; these symptoms are often incapacitating.
Migraine is highly prevalent, affecting approximately 1 in 7
individuals, and is associated with significant disability leading
to high personal, family, societal, and economic burden. Despite
its prevalence and the availability of treatments, migraine is an
underdiagnosed and undertreated disease. There is a need for new
treatments for migraine with improved benefit-risk profiles to
fulfill this unmet need.
Allergan, a leader in the migraine space, markets BOTOX®
(onabotulinumtoxinA) the first FDA-approved, preventive
treatment for adult Chronic Migraine patients since it was approved
in 2010. Allergan is also advancing its migraine program
with two investigational small molecule oral calcitonin
gene-related peptide (CGRP) receptor antagonists, which are being
developed for the acute treatment and prevention of
migraine. The U.S. FDA has accepted the company's New Drug
Application (NDA) for ubrogepant for the acute treatment of
migraine in adults, and a PDUFA date is expected in the fourth
quarter of 2019. Ubrogepant is expected to be the first oral CGRP
receptor antagonist to market. In addition, atogepant is currently
in Phase 3 development for the prevention of migraine.
About Allergan MIND™
As part of Allergan's ongoing commitment to innovating
and inspiring change in the migraine community, the company has
established a migraine franchise, Allergan MIND™ (Migraine:
Innovation, Navigation, Discovery), to drive progress and unify its
efforts as a worldwide leader in migraine. Allergan
MIND™ represents the company's vision and mission to continue
advancing science and improving the lives of people living with
migraine disease with treatments, education and support in the
pursuit of migraine freedom. This new migraine franchise serves as
a center of excellence and catalyst for advancing the dialogue and
treatment landscape in migraine, bringing together diverse
stakeholders to rally around the latest insights and developments
that will impact the future of migraine.
About Allergan plc
Allergan plc (NYSE: AGN),
headquartered in Dublin, Ireland,
is a global pharmaceutical leader focused on developing,
manufacturing and commercializing branded pharmaceutical, device,
biologic, surgical and regenerative medicine products for patients
around the world. Allergan markets a portfolio of leading brands
and best-in-class products primarily focused on four key
therapeutic areas including medical aesthetics, eye care, central
nervous system and gastroenterology. As part of its approach to
delivering innovation for better patient care, Allergan has built
one of the broadest pharmaceutical and device research and
development pipelines in the industry.
With colleagues and commercial operations located in
approximately 100 countries, Allergan is committed to working with
physicians, healthcare providers and patients to deliver innovative
and meaningful treatments that help people around the world live
longer, healthier lives every day.
For more information, visit Allergan's website
at www.Allergan.com.
Forward-Looking Statement
Statements contained in
this press release that refer to future events or other
non-historical facts are forward-looking statements that reflect
Allergan's current perspective on existing trends and information
as of the date of this release. Actual results may differ
materially from Allergan's current expectations depending upon a
number of factors affecting Allergan's business. These factors
include, among others, the difficulty of predicting the timing or
outcome of FDA approvals or actions, if any; the impact of
competitive products and pricing; market acceptance of and
continued demand for Allergan's products; the impact of uncertainty
around timing of generic entry related to key products, including
RESTASIS®, on our financial results; risks associated
with divestitures, acquisitions, mergers and joint ventures; risks
related to impairments; uncertainty associated with financial
projections, projected cost reductions, projected debt reduction,
projected synergies, restructurings, increased costs, and adverse
tax consequences; difficulties or delays in manufacturing; and
other risks and uncertainties detailed in Allergan's periodic
public filings with the Securities and Exchange Commission,
including but not limited to Allergan's Annual Report on Form 10-K
for the year ended December 31, 2018
and Allergan's Quarterly Report on Form 10-Q for the period ended
March 31, 2019. Except as expressly
required by law, Allergan disclaims any intent or obligation to
update these forward-looking statements.
CONTACTS:
|
Allergan:
|
|
Investors:
|
|
Manisha Narasimhan,
PhD
|
|
(862)
261-7162
|
|
|
|
Media:
|
|
Lisa Brown
|
|
(862)
261-7320
|
|
|
|
Julie
Ciardiello
|
|
(732)
429-4909
|
View original content to download
multimedia:http://www.prnewswire.com/news-releases/allergan-continues-to-demonstrate-leadership-in-migraine-with-29-presentations-at-the-2019-american-headache-society-annual-meeting-300881417.html
SOURCE Allergan plc